A customer in france notified biomérieux of a false negative result for an eqa ctcb 1711 sample associated with vidas® toxo igm.An investigation was performed.The report from ctcb ( centre toulousain pour le contrôle de qualité en biologie clinique - eqa french provider) was reviewed, whereas, ctcb toxo 171 - sample 1711, was found negative by three participants when it was expected to be positive with vidas® toxo igm (reference (b)(4)).Results for ctcb toxo 171 - sample 1711 were as follows : 75 participants gave a positive result as expected, 24 participants gave an equivocal result, 3 participants gave a negative result.A review of quality records confirmed the manufacturing of vidas® toxo igm lots, 170608-0 / 171213-0 / 180213-0 and 170718-0, were within specification.The ctcb toxo 171 sample 1711 was tested and the result was positive on vidas® toxo igm lots 170608-0, 171213-0 and lot 180213-0.A complementary avidity test was performed for the external quality control ctcb toxo 171 sample 1711, and gave a high avidity result.According to the package insert, a result of avidity higher than 0.300 indicates an old infection, older than 4 months.The conclusion of a probable old infection for external quality controls ctcb toxo 171 samples 1712, is coherent with the age of pregnancy indicated in ctcb report (10 weeks for sample 1711).Hypothetis : eqa ctcb 171 sample 1712 contains residual igm which are not detected by vidas technique.Vidas toxo igm detects igm for a shorter period of time than other competitors.It is acceptable to obtain a doubtful result in a context of old infection, especially more than the sensitivity is higher than 90% in the context of a recent infection (cnr publication - j.Clin.Microbiol.-2016-villard-3034-42).The external quality controls are composed of human matrix.Eqa are manufactured and cannot be considered as natural samples from patient.In conclusion, there is no performance issue and vidas® toxo igm performed as expected.
|